A Single-arm Trial, Open-label, Repeated, Long-term, Multi-center, Phase IV Clinical Trial to Evaluate the Long-term Efficacy and Safety of Repeat Treatment of Glabellar Lines With CORETOX®
Latest Information Update: 07 Jul 2022
At a glance
- Drugs Protein-free-botulinum-toxin-A-Medytox (Primary)
- Indications Glabellar lines
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Sponsors Medytox
Most Recent Events
- 27 Jul 2020 Status changed from recruiting to active, no longer recruiting.
- 26 Feb 2020 New trial record